Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Vaccines and Antiviral Agents

Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments

Thomas D. Wu, Celia A. Schiffer, Matthew J. Gonzales, Jonathan Taylor, Rami Kantor, Sunwen Chou, Dennis Israelski, Andrew R. Zolopa, W. Jeffrey Fessel, Robert W. Shafer
Thomas D. Wu
1Department of Biochemistry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celia A. Schiffer
2Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Gonzales
3Division of Infectious Diseases, Department of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Taylor
4Department of Statistics, Stanford University, Stanford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rami Kantor
3Division of Infectious Diseases, Department of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunwen Chou
5Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis Israelski
3Division of Infectious Diseases, Department of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew R. Zolopa
3Division of Infectious Diseases, Department of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Jeffrey Fessel
6AIDS Research, Kaiser-Permanente, Northern California, San Francisco, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert W. Shafer
3Division of Infectious Diseases, Department of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rshafer@stanford.edu
DOI: 10.1128/JVI.77.8.4836-4847.2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Histograms of mutation frequency according to the number of protease inhibitors (PIs) received. The median number of mutations (differences from the consensus B sequence) increased from 4 in untreated persons to 12 in persons receiving ≥4 inhibitors.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    PCA of the 45 positions associated with protease inhibitor treatment. The graph is a two-dimensional projection of the distances among the 45 positions, where the similarity between any two positions is measured by their binary (phi) correlation coefficient among persons who have received at least one inhibitor. Positions with high degrees of comutation are close together, and positions with low or negative degrees of comutation are far apart. These relationships are modeled as consistently as possible within the framework of a two-dimensional plot.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    The 50 most highly correlated residues in isolates from treated persons are shown superimposed on the locations of these residues within the folded enzyme. The blue lines represent positively correlated residues (n = 44; phi > 0.2); the red lines represent negatively correlated residues (n = 7; phi < −0.2). The diameter of each line is proportional to the correlation coefficient of the residue pair. The lines connect the beta carbons of each residue, with the exception of the glycines at positions 48 and 73, which are connected to other residues by their alpha carbons. Each correlated pair is shown twice, once in each monomer.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Six representative clusters from Table 4. Each position in a cluster demonstrates statistically significant mutational covariation with each of the other positions within a cluster. (A) Positions 10, 63, 71, 90, and 93; (B) positions 10, 46, 71, 90, and 93; (C) positions 10, 71, 73, 84, and 90; (D) positions 10, 46, 71, 84, and 90; (E) positions 10, 48, 54, and 82; (F) positions 10, 24, 46, 54, and 82. The clusters are only shown on one monomer of the protease dimer. The side chains of the residues within each cluster are shown on the protease backbone. Oxygen is shown in red, nitrogen in blue, carbon in gray, and sulfur in yellow.

Tables

  • Figures
  • TABLE 1.

    HIV-1 isolates and protease inhibitor exposurea

    No. of PIsNo. of isolatesNo. of persons treated with:
    APVIDVLPVNFVRTVSQV
    01,004000000
    163725232017561144
    2180711231004791
    3234301841116161210
    4-6189531825177187183
    Total2,2441157108568456628
    • ↵ a PI, protease inhibitor; APV, amprenavir; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir.

  • TABLE 2.

    Mutation frequencies at protease positions 1 to 99 according to the number of protease inhibitors received

    PositionaaabMutation frequency at no. of PIscAssociation with PIs (P)dAssociation with no. of PIseCommon substitutionsf
    0123≥4CoefficientP
    1P0.00.00.00.00.0
    2Q0.20.20.60.00.0
    3I0.40.02.20.00.0
    4T0.10.00.60.40.5
    5L0.00.50.60.40.0
    6W0.10.30.60.90.5
    7Q0.20.20.00.90.0
    8R0.30.20.00.40.0
    9P0.20.00.00.00.5
    10 L11.633.852.269.277.2<1.0e-9 g 0.66<1.0e-9 IVFR
    11 h V0.20.61.13.03.7 1.6e-3 0.60 4.7e-4 I
    12T11.68.37.26.010.66.6e-30.027.6e-1SPAKEI
    13 h I12.521.023.915.815.9 8.0e-6 −0.115.2e-2V
    14K11.012.210.09.09.59.9e-1−0.111.5e-1R
    15I15.018.514.421.421.71.7e-20.072.6e-1V
    16G2.62.82.22.13.79.3e-10.029.0e-1EA
    17G0.30.30.60.40.5
    18Q2.01.71.71.73.29.5e-10.192.5e-1H
    19L8.69.713.39.413.21.0e-10.082.8e-1IVTQ
    20 K1.612.119.427.829.6<1.0e-9 0.37<1.0e-9 RIMT
    21E0.20.00.00.00.0
    22 h A0.00.60.01.71.6 7.2e-3 i 0.331.6e-1V
    23 h L0.10.62.23.81.6 5.0e-4 0.345.0e-1I
    24 L0.15.25.610.79.5<1.0e-9 0.247.5e-3I
    25D0.00.20.00.90.0
    26T0.00.00.00.00.0
    27G0.00.00.00.00.0
    28A0.00.00.00.90.0
    29D0.30.00.00.40.0
    30 D0.013.812.23.43.2<1.0e-9 −0.54 1.4e-8 N
    31T0.10.20.00.00.0
    32 V0.04.23.93.86.3<1.0e-9 0.113.2e-1I
    33 L2.94.74.47.314.8 5.9e-5 0.41 3.0e-6 FIV
    34 h E0.50.92.83.04.8 1.6e-3 0.51 4.7e-4 QD
    35 h E24.028.728.932.139.7 2.6e-4 0.131.3e-2DG
    36 M13.327.830.633.844.4<1.0e-9 0.20 5.6e-4 IVL
    37N34.634.531.135.035.49.2e-10.017.7e-1DSTEHCA
    38L0.50.50.60.00.59.9e-1−0.156.9e-1
    39P3.23.51.11.32.64.7e-1−0.231.6e-1SQ
    40G0.10.20.00.00.0
    41R21.917.019.422.619.06.8e-10.072.6e-1K
    42W0.00.00.00.00.5
    43 h K2.12.87.87.37.9 2.4e-4 0.31 1.6e-3 TR
    44P0.10.00.00.00.0
    45 h K0.43.00.63.84.2 1.1e-5 0.142.9e-1KR
    46 M0.222.438.942.751.3<1.0e-9 0.41<1.0e-9 ILV
    47 I0.32.21.11.73.2 3.7e-4 0.105.3e-1V
    48 G0.13.55.612.810.1<1.0e-9 0.40 8.5e-6 V
    49G0.10.00.00.00.0
    50 I0.11.40.60.91.4 5.0e-4 0.402.1e-2V
    51G0.10.30.60.90.0
    52G0.10.20.00.00.0
    53 F0.41.45.011.115.3<1.0e-9 0.68<1.0e-9 LY
    54 I0.313.220.642.746.0<1.0e-9 0.60<1.0e-9 VLTM
    55 h K0.72.24.403.47.4 1.3e-5 0.362.4e-3R
    56V0.00.00.00.00.0
    57R7.58.58.38.115.91.0e-10.163.7e-2K
    58 h Q0.32.73.96.87.4 2.9e-9 0.36 9.7e-4 E
    59Y0.30.20.00.00.0
    60 D3.76.47.213.713.8 1.0e-6 0.28 3.8e-4 E
    61Q3.62.76.75.15.85.3e-10.233.2e-2ENH
    62 h I17.227.832.836.344.4<1.0e-9 0.21 1.4e-5 V
    63 L68.082.690.691.596.8<1.0e-9 0.52<1.0e-9 PSAQTCHV
    64I21.225.918.922.621.22.1e-1−0.099.8e-2VLM
    65E2.02.02.21.31.18.2e-1−0.212.6e-1D
    66 h I0.11.43.92.63.2 1.6e-5 0.211.7e-1FV
    67C1.92.43.31.75.32.0e-10.201.3e-1SFY
    68G0.20.00.60.50.4
    69H5.45.27.26.011.12.9e-10.247.8e-3HKYR
    70K3.53.32.24.31.66.6e-1−0.104.7e-1RQ
    71 A6.834.450.057.369.3<1.0e-9 0.46<1.0e-9 VTI
    72 h I8.315.213.921.816.4 1.1e-8 0.082.3e-1VTMLE
    73 G0.06.114.427.434.9<1.0e-9 0.66<1.0e-9 STC
    74 h T0.26.69.47.78.5<1.0e-9 0.074.5e-1SPA
    75 h V0.11.31.72.10.0 2.8e-3 −0.145.1e-1I
    76 h L0.11.32.21.30.5 2.8e-3 −0.145.1e-1V
    77 V23.428.636.734.634.9 1.2e-5 0.113.0e-2I
    78G0.00.00.00.00.0
    79 h P0.00.51.71.74.2 3.2e-4 0.59 9.1e-4 A
    80T0.00.00.00.00.0
    81P0.00.20.00.00.0
    82 V1.225.033.346.242.3<1.0e-9 0.30 1.6e-9 ATFI
    83 h N0.00.51.10.91.6 1.1e-2 i 0.312.1e-1D
    84 I0.05.016.124.836.5<1.0e-9 0.71<1.0e-9 V
    85 h I0.22.81.74.75.7 9.3e-8 0.263.6e-2V
    86G0.00.20.00.00.0
    87R0.60.00.01.30.0
    88 N0.29.18.96.87.4<1.0e-9 −0.093.2e-1DS
    89 h L0.71.45.07.34.2 1.9e-5 0.41 6.3e-4 MVI
    90 L0.122.340.655.666.7<1.0e-9 0.64<1.0e-9 M
    91T0.60.20.00.40.0
    92 h Q0.92.43.93.83.2 6.3e-4 0.162.4e-1KR
    93 I24.134.536.742.348.7<1.0e-9 0.17 3.0e-4 LM
    94G0.00.00.00.00.0
    95 h C0.30.62.23.83.2 1.3e-3 0.473.1e-3F
    96T0.00.00.00.00.0
    97L0.10.00.00.00.0
    98N0.30.20.00.00.0
    99F0.00.00.60.00.0
    • ↵ a Positions that were associated with PIs are in boldface.

    • ↵ b aa, amino acid.

    • ↵ c PIs, protease inhibitors.

    • ↵ d Chi-square test of independence between presence of mutation and having received a PI.

    • ↵ e Logistic regression of the occurrence of mutation on the number of PIs. P values are shown for the 62 variable positions. Coefficient, logistic regression coefficient.

    • ↵ f Mutations occurring in five or more isolates listed in the order of frequency.

    • ↵ g P values in bold were significant at an FDR of 0.01 following correction for multiple comparisons.

    • ↵ h Newly described treatment-associated mutations.

    • ↵ i A22V and N83D were significant at an FDR of 0.05.

  • TABLE 3.

    Most strongly correlated pairs of positions among 115 statistically significant correlations in isolates from treated personsa

    Pos 1Pos 2Residue role(s)bPhiP valuec(Å) DistancedCorrelations between specific amino acids
    Pos 1Pos 2PhiP valuec
    Positive correlations
        8254Substrate cleft/flap0.63<1.0e-95.682A54V0.55<1.0e-9
        82A54T0.21<1.0e-9
        82T54V0.157.5e-7
        82I54M0.151.4e-4
        3247Substrate cleft/flap0.51<1.0e-93.932I47V0.51<1.0e-9
        907390M/accessory0.47<1.0e-98.990M73S0.38<1.0e-9
        90M73T0.181.0e-9
        3635Accessory/polymorphism0.45<1.0e-91.336I35D0.45<1.0e-9
        5410Flap/accessory0.41<1.0e-916.354V10I0.38<1.0e-9
        2036Accessory/accessory0.41<1.0e-93.220R36I0.40<1.0e-9
        3088Substrate cleft/accessory0.40<1.0e-93.530N88D0.52<1.0e-9
        907190M/accessory0.38<1.0e-96.390M71V0.30<1.0e-9
        1071Accessory/accessory0.37<1.0e-915.110I71V0.32<1.0e-9
        901090M/accessory0.35<1.0e-910.190M10I0.27<1.0e-9
        8210Substrate cleft/accessory0.35<1.0e-94.882A10I0.32<1.0e-9
        82T10R0.25<1.0e-9
        4610Flap/accessory0.35<1.0e-917.746I10I0.168.0e-8
        46L10I0.151.5e-7
        5471Flap/accessory0.34<1.0e-920.454V71V0.32<1.0e-9
        7793Accessory/accessory0.31<1.0e-917.677I93L0.20<1.0e-9
        8410Substrate cleft/accessory0.30<1.0e-97.884V10I0.28<1.0e-9
        8490Substrate cleft/90M0.30<1.0e-97.684V90M0.29<1.0e-9
        4854Substrate cleft/flap0.29<1.0e-95.048V54T0.44<1.0e-9
        48V54V0.181.5e-9
        1219Polymorphism/polymorphism0.29<1.0e-94.212E19I0.26<1.0e-9
        8473Substrate cleft/accessory0.28<1.0e-910.584V73S0.23<1.0e-9
        4624Flap/accessory0.27<1.0e-918.846L24I0.20<1.0e-9
        46I24I0.166.1e-8
        1073Accessory/accessory0.27<1.0e-918.910I73S0.18<1.0e-9
        8271Substrate cleft/accessory0.26<1.0e-916.582A71V0.27<1.0e-9
        8224Substrate cleft/accessory0.26<1.0e-97.582A24I0.28<1.0e-9
        3537Polymorphism/polymorphism0.26<1.0e-94.635D37D0.18<1.0e-9
        35D37E0.175.2e-9
        5424Flap/accessory0.26<1.0e-915.824I54V0.29<1.0e-9
        3662Accessory/polymorphism0.26<1.0e-97.336I62V0.21<1.0e-9
        8248Substrate cleft/substrate cleft0.25<1.0e-97.682A48V0.27<1.0e-9
        8471Substrate cleft/accessory0.25<1.0e-911.084V71V0.23<1.0e-9
        8246Substrate cleft/flap0.25<1.0e-914.182A46L0.28<1.0e-9
        906390M/accessory0.23<1.0e-911.490M63P0.31<1.0e-9
        902090M/accessory0.22<1.0e-912.990M20I0.19<1.0e-9
        909390M/accessory0.22<1.0e-93.390M93L0.21<1.0e-9
        1093Accessory/accessory0.22<1.0e-910.610I93L0.20<1.0e-9
        4655Flap/polymorphism0.22<1.0e-93.846I55R0.154.7e-7
        1214Polymorphism/polymorphism0.22<1.0e-94.412P14R0.31<1.0e-9
        1024Accessory/accessory0.22<1.0e-95.010I24I0.22<1.0e-9
        3075Substrate cleft/nonpolymorphic0.22<1.0e-96.730N75I0.22<1.0e-9
        5420Flap/accessory0.22<1.0e-914.520R54V0.24<1.0e-9
        6061Accessory/polymorphism0.21<1.0e-91.360E61E0.24<1.0e-9
        4810Substrate cleft/accessory0.21<1.0e-913.310I48V0.22<1.0e-9
        7173Accessory/accessory0.21<1.0e-94.171V73A0.27<1.0e-9
        71I73T0.24<1.0e-9
        7362Accessory/polymorphism0.20<1.0e-92.973S62V0.19<1.0e-9
        8479Substrate cleft/Nonpolymorphic0.20<1.0e-98.284V79A0.163.4e-7
    Negative correlations
        3677Accessory/accessory−0.34<1.0e-93.436I77I−0.31<1.0e-9
        7164Accessory/polymorphism−0.23<1.0e-92.971V64V−0.181.0e-9
        6364Accessory/polymorphism−0.22<1.0e-91.363P64V−0.25<1.0e-9
        3082Substrate cleft/substrate cleft−0.22<1.0e-98.830N82A−0.172.4e-9
        3090Substrate cleft/90M−0.21<1.0e-97.930N90M−0.20<1.0e-9
        3010Substrate cleft/accessory−0.20<1.0e-913.330N10I−0.18<1.0e-9
        902490M/accessory−0.20<1.0e-93.890M24I−0.19<1.0e-9
    • ↵ a The 43 positive correlations with phi of ≥0.20 and the 7 negative correlations with phi of ≤−0.20. Correlations between specific amino acids at these positions are shown for those cases where phi ≥ 0.15 or phi ≤ −0.15. Pos, position.

    • ↵ b Substrate cleft residues are directly in contact with one or more inhibitors. Residues in the flap and at position L90M often directly confer or contribute to protease inhibitor resistance even though they are not in direct inhibitor contact. Accessory mutations contribute to resistance only when present with a mutation in the substrate cleft or flap or at position 90. Of the polymorphisms in this table, those at positions 35, 55, and 62 are significantly associated with drug therapy, whereas those at positions 12, 14, 19, 37, and 64 are not associated with drug therapy (Table 2). The nonpolymorphic residues at positions 75 and 79 are significantly associated with drug therapy (Table 2). The substrate cleft residues at positions 48 and 50 are also in the flap.

    • ↵ c P values shown have not been corrected for multiple comparisons.

    • ↵ d The distance between two residues was considered to be the shortest interatomic distance between each of the atoms in the two residues. Residues 82 and 54 are 8.3 Å apart in the 1hsg structure (3) but only 5.6 Å apart in the molecular-dynamics simulation, both described in Materials and Methods (23). The remaining distances are based on the 1hsg structure.

  • TABLE 4.

    Clusters of correlated protease positions

    Primary mutationOther mutationsClusteraNo. (%) of isolates
    Treated isolates
        L90ML10I ± A71VT ± G73S 10 63 71 90 93 118 (9.5)
    10 63 71 73 9082 (6.6)
    10 62 63 90 9375 (6.0)
    10 62 63 73 9062 (5.0)
    10 20 71 73 9024 (1.9)
    10 20 62 73 9020 (1.6)
    L10I ± M46I ± I84V 10 46 71 90 93 56 (4.5)
    10 (30) 73 84 9053 (4.3)
    10 (30) 46 84 9047 (3.8)
    10 71 73 84 90 42 (3.4)
    10 46 71 84 90 34 (2.7)
    10 24 46; 10 46 90b 52 (4.2); 142 (11.4)b
        V82AM46I ± I54V10 (30) 46 54 8282 (6.6)
    10 48 54 82 40 (3.2)
    10 24 46 54 82 32 (2.6)
    32 46 8223 (1.9)
    10 46 53 54 71 826 (0.5)
        D30NN88D30 (82) 8844 (3.5)
    13 30 8818 (1.5)
    30 75 883 (0.2)
        NoneM46I ± I54V10 46 63 71 9382 (6.6)
    20 36 5475 (6.0)
    10 20 54 7157 (4.6)
    Miscellaneous63 (64) 71417 (33.6)
    10 77 93134 (10.8)
    20 36 6273 (5.8)
    20 35 36 (77)70 (5.6)
    15 20 36 (77)41 (3.3)
    10 24 8911 (0.9)
    10 20 73; 10 73 77c 36 (2.9); 69 (5.6)c
    Untreated isolates
        NoneA71VT + I93L71, 77, 9325 (0.2)
    62, 63, 71, 9322 (0.2)
    • ↵ a Clusters in boldface are shown in Fig. 4. Residues within parentheses are negatively correlated with the other residues in the cluster.

    • ↵ b 10 + 46 + 90 occurred in 142 isolates; 10 + 24 + 46 occurred in 52 isolates; 24 and 90 were negatively correlated.

    • ↵ c 10 + 73 + 77 occurred in 69 isolates; 10 + 20 + 73 occurred in 36 isolates; 20 and 77 were negatively correlated.

PreviousNext
Back to top
Download PDF
Citation Tools
Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments
Thomas D. Wu, Celia A. Schiffer, Matthew J. Gonzales, Jonathan Taylor, Rami Kantor, Sunwen Chou, Dennis Israelski, Andrew R. Zolopa, W. Jeffrey Fessel, Robert W. Shafer
Journal of Virology Apr 2003, 77 (8) 4836-4847; DOI: 10.1128/JVI.77.8.4836-4847.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments
Thomas D. Wu, Celia A. Schiffer, Matthew J. Gonzales, Jonathan Taylor, Rami Kantor, Sunwen Chou, Dennis Israelski, Andrew R. Zolopa, W. Jeffrey Fessel, Robert W. Shafer
Journal of Virology Apr 2003, 77 (8) 4836-4847; DOI: 10.1128/JVI.77.8.4836-4847.2003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

HIV Infections
HIV Protease
HIV Protease Inhibitors
HIV-1
mutation

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514